May. 20, 2011

European Review Board Issues Positive Opinion for Benlysta®

May 20, 2011 


GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (HGSI) have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for BENLYSTA® (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy.  Read the entire release published on the HGSI website


Related Stories

General News | Oct. 31, 2011

Lupus Organizations Around the Globe Urge NICE to Provide Coverage for Benlysta®

National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.

General News | Jul. 13, 2011

Health Canada and European Medicines Agency Approves BENLYSTA™

Health Canada and European Regulators have approved BENLYSTA™.